Study of Real Clinical Practice to Evaluate the Effects of Oral Dydrogesterone for Treatment of Confirmed Endometriosis

Launched by ABBOTT · Sep 28, 2018

Keywords

ClinConnect Summary

A non-interventional, observational program to assess the effects of oral dydrogesterone therapy in a post-marketing setting whether the effects are related to the regimen of dydrogesterone therapy. In this observational program, assuming that dydrogesterone plays a role in the treatment of endometriosis without suppression of ovulation, the goal is to observe the possible implications of such treatment in terms of treatment regimen and response pattern. In the study will be described effects of Duphaston® 6-months-administration in patients with confirmed endometriosis by assessing pain re...

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Female, aged ≥ 18 years and ≤ 45 years.
• • Complaints on chronic pelvic pain with or without dysmenorrhea assessed by 11-items NRS.
• • External genital endometriosis confirmed by laparoscopy.
• • Existing pelvic (vaginal) ultrasound data not earlier than 2 months before inclusion in the study.
• • Prescribed treatment with Duphaston® according local labelling for treatment of endometriosis 10 mg 2-3 times a day from the 5th to the 25th day of the menstrual period cycle or continuously.
• • No hormonal treatment in 2 cycles before enrollment.
• • Signed Patient Authorization for Use/Disclosure of Data.
• Exclusion Criteria:
• • Any co-existing disease(s) needing chronic drug therapy (e.g. Crohn's disease, diabetes etc); Severe concomitant medical illness.
• • Severe other genital pathology excluding endometriosis (e.g. Multiple/severe myoma; adenomyosis, inflammatory diseases, etc.).
• • Routine consumption of analgesics other than for the pain of endometriosis.
• • Patients receiving hormonal contraceptives in last 2 cycles (including intrauterine devices, contraceptive patches, contraceptive rings, oral contraceptives etc.).
• • Ongoing pregnancy.
• • Menopause or premature ovarian failure.
• • Contraindications to dydrogesterone treatment listed in the locally approved label (Instructions for the medical use of Duphaston®).
• • Any other condition that precludes use of dydrogesterone in a particular patient, in accordance with the precautions and special warnings listed in the locally approved label (Instructions for the medical use of Duphaston®).
• • Abnormal results of pap smear test.
• • Other conditions that made the patients participation impossible (based on the investigator decision).
• • Fertility treatments using assisted reproductive technology.